Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.

about

Low muscle quality in Japanese type 2 diabetic patients with visceral fat accumulation

P2860

Q58800695-3B48F162-F632-4AAB-A0D9-48425100A3D7

P2860

Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.

Item

http://www.wikidata.org/entity/Q47603611

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Dipeptidyl peptidase 4 inhibit ...... patients with type 2 diabetes.

@en

Dipeptidyl peptidase 4 inhibit ...... patients with type 2 diabetes.

@nl

type

Item

label

Dipeptidyl peptidase 4 inhibit ...... patients with type 2 diabetes.

@en

Dipeptidyl peptidase 4 inhibit ...... patients with type 2 diabetes.

@nl

prefLabel

Dipeptidyl peptidase 4 inhibit ...... patients with type 2 diabetes.

@en

Dipeptidyl peptidase 4 inhibit ...... patients with type 2 diabetes.

@nl

P1476

Dipeptidyl peptidase 4 inhibit ...... patients with type 2 diabetes

@en

P2093

Hajime Izumiyama

http://www.w3.org/2001/XMLSchema#string

Isao Minami

http://www.w3.org/2001/XMLSchema#string

Koshi Hashimoto

http://www.w3.org/2001/XMLSchema#string

Masanori Murakami

http://www.w3.org/2001/XMLSchema#string

Takanobu Yoshimoto

http://www.w3.org/2001/XMLSchema#string

Takato Takeuchi

http://www.w3.org/2001/XMLSchema#string

Tatsuya Fukuda

http://www.w3.org/2001/XMLSchema#string

Yoshihiro Ogawa

http://www.w3.org/2001/XMLSchema#string

Yujiro Nakano

http://www.w3.org/2001/XMLSchema#string

P2860

Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People

Insulin resistance and sarcopenia: mechanistic links between common co-morbidities

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

Association of diabetes, comorbidities, and A1C with functional disability in older adults: results from the National Health and Nutrition Examination Survey (NHANES), 1999-2006

Frailty consensus: a call to action.

A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach.

Diabetes mellitus, fasting glucose, and risk of cause-specific death.

Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease.

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.

P31

scholarly article

P356

10.1002/DMRR.2957

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Ryotaro Bouchi

P577

2017-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29054111

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.

about

P2860

P2860

Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P31

P356

P433

P478

P50

P577

P698

P921